Pharmacokinetics and metabolism of intravenous pirfenidone in sheep

被引:14
作者
Bruss, Michael L. [1 ]
Stanley, Scott D. [2 ]
Margolin, Solomon B. [3 ]
Giri, Shri N. [2 ,3 ]
机构
[1] Univ Calif Davis, Sch Vet Med, Dept Anat Physiol & Cell Biol, Davis, CA 95616 USA
[2] Univ Calif Davis, Dept Mol Biosci, Sch Vet Med, Davis, CA 95616 USA
[3] Marnac Inc, Dallas, TX USA
关键词
pirfenidone; sheep; pharmacokinetics; metabolism;
D O I
10.1002/bdd.595
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pirfenidone, a promising antifibrotic agent, was administered intravenously to six female sheep at 30 mg/kg. Four sheep received C-14-pirfenidone simultaneously. Plasma and urine were obtained for assay of pirfenidone and its metabolites over two days, and tissues were obtained via necropsy. Samples were analysed for pirfenidone and metabolites using HPLC-MS and flow scintillation spectrometry. Plasma pirfenidone disappeared with first order kinetics with a clearance of 1.2 l/kg/h, half-life of 24 min, and distribution volume of 0.71 l/kg. After 48 h, the organs containing the largest quantity of C-14 were lungs, liver and intestinal wall. Tissues with the highest concentration of C-14 were lung, kidney, brain, liver, lymph node and adipose. Metabolites found in plasma and urine were hydroxypirfenidone (half-life of 44min) and carboxypirfenidone. Additional metabolites found in urine were hydroxypirfenidone glucuronide and acetoxypirfenidone. Approximately, 80% of the tracer eventually appeared in the urine, and approximately 50% of it was in the form of identifiable metabolites. Less than 1% of the dose appeared in the urine in the form of the parent drug. Quantitatively, most of the metabolites appeared in the urine within 2h. Thus, the drug is rapidly and completely metabolized. Copyright (C) 2008 John Wiley & Sons, Ltd.
引用
收藏
页码:119 / 126
页数:8
相关论文
共 18 条
  • [11] RADOSTITS OM, 1999, VET MED TXB DIS CATT, P335
  • [12] Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone - Results of a prospective, open-label phase II study
    Raghu, G
    Johnson, WC
    Lockhart, D
    Mageto, Y
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (04) : 1061 - 1069
  • [13] ROWLAND M, 1995, CLIN PHARMACOKINET, P424
  • [14] SHARGEL L, 1993, APPL BIOPHARMACEUTIC, P299
  • [15] Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats
    Tada, S
    Nakamuta, M
    Enjoji, M
    Sugimoto, R
    Iwamoto, H
    Kato, M
    Nakashima, Y
    Nawata, H
    [J]. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2001, 28 (07): : 522 - 527
  • [16] Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients
    Taniyama, M
    Ohbayashi, S
    Narita, M
    Nakazawa, R
    Hasegawa, S
    Azuma, N
    Teraoka, S
    Ota, K
    Yamauchi, S
    Margolin, SB
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 52 (01) : 77 - 78
  • [17] A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis
    Walker, JE
    Giri, SN
    Margolin, SB
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2005, 11 (02) : 149 - 158
  • [18] Pirfenidone for chronic progressive multiple sclerosis
    Walker, JE
    Margolin, SB
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2001, 7 (05) : 305 - 312